Home | Find A Doctor | Contact Us


Phase I Trial of Stereotactic Body Radiotherapy (SBRT) of the Primary Tumor in Renal Cell Carcinoma (RCC)

Principal Investigator: Ronald Ennis, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai West


Continuum Cancer Research Program
(212) 844-6286


The current standard technique is surgery or percutaneous ablative (sticking needles through the skin) techniques such as radiofrequency ablation (destroying the tumor with energy) and cryosurgery (procedure to destroy the tumor by freezing it). The study treatment, known as stereotactic body radiation therapy (SBRT), uses highly focused beams of radiation aimed at the kidney tumor to destroy it. The treatment is given as three outpatient radiation treatments given over one and a half weeks. The purpose of the study is to see what kind of side effects occurs to patients treated with stereotactic body radiation to the kidney and how often they occur. We are also evaluating how successful the treatment is.

Eligibility and Treatment Plan:

  • Male and female of at least 18 years old
  • Ability to lie still for approximately 1 hour in immobilization device
  • Any patient with a primary renal cell carcinoma (RCC) tumor who is medically inoperable or who declines surgery for resectable RCC
  • Adequate renal function, as measured by creatinine clearance calculated from 24 hour urine collection
  • No prior attempt at medicinal treatment of this primary kidney tumor

Please call for more information



Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System